News Roundup | UK-based Meta Analysis On Ivermectin Peer Reviewed & Published

Article 1 | UK-based Meta Analysis Peer Reviewed & Published Suggests Ivermectin A Key Public Health Weapon in the War Against COVID-19:
Recently published in the peer-reviewed American Journal of Therapeutics, Dr. Tess Lawrie, an expert in medicinal evidence, along with other experts in population health and gastroenterology out of the United Kingdom (UK), conducted a comprehensive meta-analysis involving the certainty of evidence using an approach known as GRADE, which led to the focus on twenty-four ivermectin-centered randomized controlled trials involving 3,406 participants.

Article Link | https://trialsitenews.com/uk-based-meta-analysis-peer-reviewed-published-suggests-ivermectin-a-key-public-health-weapon-in-the-war-against-covid-19/

Article 2 | Breaking News Novavax’ Traditional Vaccine Brings Imminent Competition to the Genetic-based Vaccines Currently Under EUA:
U.S-based Novavax (Nasdaq: NVAX) reports today that its COVID-19 vaccine candidate called NVX-CoV2373 or “Coronavax” demonstrated 100% protection against moderate and severe disease and 90.4% overall efficacy, keeping this investigational product competitive with both mRNA-based vaccine products under emergency use authorization (EUA) as well as superior to the Johnson and Johnson Adenovirus-based vaccine, which is also authorized for deployment in the USA on an emergency basis.

Article Link | https://trialsitenews.com/breaking-news-novavax-traditional-vaccine-brings-imminent-competition-to-the-genetic-based-vaccines-currently-under-eua/

Responses